The Supreme Court on Thursday blocked a Fifth Circuit order that would have forced women to visit a doctor in person before obtaining the abortion pill mifepristone, keeping the drug available by mail and telehealth while the legal fight plays out. The 7-2 decision drew fierce dissents from Justices Clarence Thomas and Samuel Alito, who argued the majority was actively undermining the post-Dobbs legal order and ignoring federal criminal law.
The ruling preserves, for now, an FDA regulation that allows mifepristone to be prescribed through telehealth, dispensed at pharmacies, and shipped directly to patients, the same framework Louisiana challenged as a threat to its near-total abortion ban. The case now returns to the New Orleans-based Fifth Circuit, and it could ultimately land back before the justices on their regular docket.
For pro-life advocates who believed the Dobbs decision returned abortion policy to the states, the order is a sharp reminder that the federal regulatory apparatus, and the Court's willingness to protect it, can override state-level restrictions with a single emergency stay.
On May 1, the U.S. Court of Appeals for the Fifth Circuit reinstated a requirement that women visit a health care provider in person to obtain mifepristone. That order reversed an FDA rule change that had opened the door to remote prescriptions and mail delivery of the drug.
Two drugmakers, manufacturers of mifepristone and a generic version, asked the Supreme Court to intervene. Justice Alito, who by default handles emergency matters from the Fifth Circuit, briefly put the ruling on hold while the full Court decided what to do.
On Thursday, a seven-justice majority sided with the drugmakers. The Washington Examiner reported the Court's 7-2 order restored nationwide access to mail-order mifepristone and paused the Fifth Circuit's ruling while the case continues.
The practical effect: nothing changes on the ground for the time being. The FDA's current rules stay in place. Women in states that permit abortion can still get the pill without walking into a clinic. And states like Louisiana, which passed a near-total ban, are left arguing that the federal government's own drug-access rules are gutting their sovereignty.
The two dissenting justices did not mince words. Thomas, in a separate dissent, invoked the Comstock Act, an 1873 anti-obscenity law, to argue that federal law already makes mailing mifepristone a criminal offense. His language was blunt:
"Applicants are not entitled to a stay of an adverse court order based on lost profits from their criminal enterprise. They cannot, in any legally relevant sense, be irreparably harmed by a court order that makes it more difficult for them to commit crimes."
That framing, calling the mail distribution of an FDA-approved drug a "criminal enterprise", signals how far apart the Court's conservatives remain on the intersection of federal drug regulation and state abortion law. Thomas's position rests on the argument that the Comstock Act, never formally repealed, bars the mailing of abortion-related materials regardless of what the FDA says.
Alito's dissent struck a different but equally pointed tone. He called the majority's decision to grant the emergency petition "remarkable," as Fox News reported, and framed the stakes in sweeping terms.
"What is at stake is the perpetration of a scheme to undermine our decision in Dobbs v. Jackson Women's Health Organization."
That accusation, that the FDA's telehealth-and-mail framework functions as an end-run around the Court's own landmark ruling returning abortion to the states, deserves serious consideration. If Dobbs meant anything, it meant that states could set their own abortion policies. A federal rule that lets pills flow across state lines by mail complicates that promise considerably.
Louisiana's position in this case is straightforward. The state argued that the FDA's rules undercut its near-total abortion ban and violated its sovereignty. It also contended that the FDA did not have sufficient safety data to roll back the in-person dispensing requirement.
That argument carries weight in a post-Dobbs landscape. The whole premise of the 2022 ruling was that the Constitution does not contain a right to abortion and that elected legislatures, not federal agencies, should decide the question. Yet the FDA's regulatory framework effectively allows women in restrictive states to obtain abortion pills through the mail, bypassing the very laws those states enacted after Dobbs gave them the green light.
The tension between federal regulatory power and state legislative authority is not unique to abortion. Recent Supreme Court decisions on redistricting and other federalism questions have shown the justices grappling with how far federal courts and agencies can reach into state governance.
But the abortion context makes the stakes sharper. For Louisiana and other states with strict bans, the FDA's mifepristone rules are not an abstract regulatory dispute. They are the mechanism by which their democratically enacted laws can be rendered partially unenforceable.
Thursday's order is not the first time the justices have stepped in to preserve mifepristone access over conservative objections. The Washington Free Beacon noted that in April 2023, the Court blocked a Texas judge's order that would have sharply limited access to the drug, keeping it available while the legal challenge continued. Thomas and Alito dissented then, too.
The New York Post reported at the time that the Court stayed a ruling that would have invalidated the FDA's original 2000 approval of mifepristone, meaning access was likely to remain unchanged for months or longer as appeals wound through the courts.
That pattern, the Court's majority consistently siding with the status quo on mifepristone access, even after Dobbs, raises uncomfortable questions for conservatives who expected the post-Roe legal environment to produce faster, more tangible results at the federal level.
It also raises questions about the Court itself. Chief Justice Roberts has pushed back on characterizations of the Court as a political body, but decisions like Thursday's inevitably fuel that perception, on both sides. Pro-life groups see a Court unwilling to follow the logic of its own Dobbs ruling. Abortion-rights advocates claim vindication while bracing for the next round.
The case returns to the Fifth Circuit, where the underlying merits will be argued. The central questions remain unresolved: Does the FDA have the authority to override state abortion restrictions through drug-access rules? Does the Comstock Act prohibit mailing mifepristone? And does a state's sovereign right to ban abortion extend to blocking federally regulated pharmaceuticals from crossing its borders?
Those are not small questions. And the fact that seven justices, including several appointed by Republican presidents, chose to preserve the regulatory status quo rather than let the Fifth Circuit's order stand suggests the legal path for pro-life advocates at the federal level is narrower than many hoped after Dobbs.
Surprising outcomes from the Supreme Court have become a recurring source of frustration for conservatives, and this decision fits that pattern. The justices who were expected to anchor a constitutionalist majority have, on this issue, repeatedly declined to disturb the FDA's expansive approach to mifepristone distribution.
The case could ultimately return to the Supreme Court on its regular docket, which would mean full briefing, oral argument, and a merits decision rather than the emergency-stay posture that has defined the litigation so far. That would give the justices, and the public, a clearer picture of where the law actually stands.
Until then, the pills keep moving through the mail. The Court's intervention preserves a federal framework that effectively limits what states can do with the authority Dobbs was supposed to give them.
If the promise of Dobbs was that the people's elected representatives would decide abortion policy, someone ought to explain why an FDA regulation and a seven-justice majority keep deciding it for them.
